Close Menu
Technology Mag

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    A European Startup’s Spacecraft Made It to Orbit. Now It’s Lost at Sea

    July 3, 2025

    ‘Persona 5: The Phantom X’ Brings the Series to Your Phone—and It’s Shockingly Good

    July 3, 2025

    Paramount Plus slashes prices to $2 for two months

    July 3, 2025
    Facebook X (Twitter) Instagram
    Subscribe
    Technology Mag
    Facebook X (Twitter) Instagram YouTube
    • Home
    • News
    • Business
    • Games
    • Gear
    • Reviews
    • Science
    • Security
    • Trending
    • Press Release
    Technology Mag
    Home » The World’s First Crispr Drug Gets a Slow Start
    Science

    The World’s First Crispr Drug Gets a Slow Start

    News RoomBy News RoomDecember 27, 20243 Mins Read
    Facebook Twitter Pinterest LinkedIn Reddit WhatsApp Email

    Deshawn “DJ” Chow waited a year to receive a treatment that could change his life. The 19-year-old was born with sickle cell disease, which makes his red blood cells crescent-shaped and sticky. The misshapen cells build up and block blood vessels, cutting off oxygen to parts of the body and causing episodes of excruciating pain. The condition affects about 100,000 people in the United States, most of them Black.

    The pain came more and more frequently for Chow in high school, landing him in the hospital often. He missed school, birthday parties, and sleepovers with friends. Sometimes, the pain lasted for days. “It’s like my body is on fire,” he says.

    A year ago, he found out about a new treatment called Casgevy that could end his years-long battle with pain. It’s the first approved medicine to use the Nobel Prize–winning technology known as Crispr, a type of gene editing. Chow received Casgevy on December 5 at City of Hope Cancer Center in Los Angeles. He is among the first patients in the US to get the treatment since its approval in December 2023. It was also approved for beta thalassemia, a related blood disorder, this January.

    Due to manufacturing complexities, insurance delays, and the extensive preparation involved for patients, few individuals in the US have been dosed with Casgevy since it became commercially available. The slow rollout underscores the complicated nature of commercializing cutting-edge medical treatments and getting them to patients. Another genetic treatment for sickle cell, Lyfgenia, won approval last December, and the first patient was treated in September. Made by Bluebird Bio, it uses an older technology that introduces a new gene to treat the disease.

    Vertex Pharmaceuticals and Crispr Therapeutics, which developed Casgevy, have not publicly said how many patients have received the therapy so far. WIRED reached out to all 34 US hospitals approved to administer it as of December. Of the 26 that provided answers, only City of Hope and Children’s National Hospital in Washington, DC, said they had administered Casgevy. (Three hospitals declined to comment, and five others did not respond to multiple inquiries.) Chow is City of Hope’s first sickle cell patient, while a beta thalassemia patient has been treated at Children’s National. Several authorized centers told WIRED they will begin infusions of Casgevy in early 2025.

    “The process of getting this drug is very different from just taking a pill,” says Leo Wang, Chow’s hematologist-oncologist at City of Hope. It is a one-time therapy that involves collecting and editing a person’s stem cells. For the patient, it means a harsh round of chemotherapy before getting the cells, and a month in the hospital afterward.

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email
    Previous ArticleOpenAI announces plan to transform into a for-profit company
    Next Article Canon R5 Mark II review: the best full-frame camera today?

    Related Posts

    A European Startup’s Spacecraft Made It to Orbit. Now It’s Lost at Sea

    July 3, 2025

    The Next Acetaminophen Tablet You Take Could Be Made From PET

    July 2, 2025

    How Much Energy Does AI Use? The People Who Know Aren’t Saying

    July 2, 2025

    Space Elevators Could Totally Work—if Earth Days Were Much Shorter

    July 2, 2025

    Methane Pollution Has Cheap, Effective Solutions That Aren’t Being Used

    July 2, 2025

    How to Make AI Faster and Smarter—With a Little Help From Physics

    July 1, 2025
    Our Picks

    ‘Persona 5: The Phantom X’ Brings the Series to Your Phone—and It’s Shockingly Good

    July 3, 2025

    Paramount Plus slashes prices to $2 for two months

    July 3, 2025

    Whoop MG review: a big whoop for a small crowd

    July 3, 2025

    Adding calendar events with a screenshot is AI at its finest

    July 3, 2025
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Don't Miss
    Gear

    What Is Apple One, and Should You Subscribe?

    By News RoomJuly 3, 2025

    What if you scored a free trial of Apple TV+ for three months, or you…

    Samsung seems to have leaked its own trifold phone design

    July 3, 2025

    ICE Rolls Facial Recognition Tools Out to Officers’ Phones

    July 3, 2025

    Google’s customizable Gemini chatbots are now in Docs, Sheets, and Gmail

    July 3, 2025
    Facebook X (Twitter) Instagram Pinterest
    • Privacy Policy
    • Terms of use
    • Advertise
    • Contact
    © 2025 Technology Mag. All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.